Trials of de-escalated neoadjuvant therapy using APT-style taxane regimens are ongoing, but multi-agent chemotherapy regimens including carboplatin or anthracyclines in addition to taxanes remain the current standard of care in neoadjuvant therapy of HER2+ breast cancer. Here, ERBB2 is linked to breast carcinoma.